Welcome to our dedicated page for Modular Medical SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. filings document a Nevada medical device issuer developing insulin delivery technology, including registration statements, material-event reports, shareholder approvals, and capital-structure changes. Disclosures cover common stock, warrants and pre-funded warrants, amendments to authorized shares, and the completed one-for-thirty reverse stock split.
MODD filings also record material agreements and financing arrangements, Nasdaq continued-listing matters, operating expense reductions, governance actions, risk-related disclosures, and securities registration information for the company’s Pivot-focused insulin pump business.
Modular Medical, Inc. (MODD) announced that its fiscal 2027 Annual Meeting of Shareholders will be held as a virtual meeting on October 23, 2026. Shareholders of record at the close of business on September 10, 2026 will be entitled to receive notice of and vote at the meeting.
Shareholder proposals and director nominations for the 2027 Annual Meeting must be received by the Company’s Secretary at its San Diego principal executive offices by 5:00 p.m. (Eastern time) on September 13, 2026, whether for inclusion in proxy materials under Rule 14a-8 or brought outside Rule 14a-8 under the Company’s bylaws. Shareholders intending to use the universal proxy rules for their own director nominees must also provide the Rule 14a-19 notice by this same deadline.
Modular Medical, Inc. is a commercial-stage diabetes device company reporting another loss-making quarter while launching its next-generation insulin patch pump. For the three months ended June 30, 2026, the company recorded a net loss of $6.486 million on total operating expenses of $6.538 million.
Cash and cash equivalents were $3.920 million, down from $6.942 million at March 31, 2026, with cash used in operations of $5.972 million. The company raised about $3.0 million via an April 2026 registered direct offering, $0.7 million from at-the-market sales in June 2026, and a further $5.1 million under the ATM program after quarter-end.
Management and the auditor state that these conditions, together with an accumulated deficit of $119.4 million and lack of revenue, raise substantial doubt about the company’s ability to continue as a going concern. At the same time, Modular received FDA clearance for its Pivot pump in April 2026 and began initial U.S. commercial shipments in June 2026, positioning the company for potential future revenue if commercialization scales.
Solas Capital Management, LLC and Frederick Tucker Golden report amended beneficial ownership of Modular Medical, Inc. common stock. They beneficially own 552,171 shares, comprising 438,095 shares of common stock and 114,076 shares issuable upon exercise of warrants.
This position represents approximately 9.99% of the common stock, calculated using 5,413,160 shares outstanding as of June 22, 2026 plus the 114,076 warrant shares. An additional 62,679 warrant shares are excluded due to a 9.99% ownership blocker provision. All 552,171 shares are reported with shared voting and dispositive power and no sole power.
Modular Medical, Inc. has a significant shareholder group led by Bleichroeder LP and related entities, which report beneficial ownership of 336,986 common shares, representing 6.23% of the company’s common stock believed to be outstanding. These shares are reported with sole voting and dispositive power and no shared power.
Bleichroeder LP, an investment adviser, also holds 110,092 additional shares issuable upon exercise of warrants, but their exercise is constrained by a 4.99% beneficial ownership limitation applied immediately after any exercise. Without this 4.99% cap, Bleichroeder indicates it would be deemed to beneficially own 447,078 shares, or 8.09% of the outstanding common stock. Dividend and sale proceeds ultimately accrue to Bleichroeder’s advisory clients.
Pathfinder Asset Management Limited, a Canadian portfolio manager and investment fund manager, reported beneficial ownership of common stock of Modular Medical, Inc.. As of June 30, 2026, Pathfinder beneficially owned 399,775 shares of Modular Medical common stock, par value $0.001 per share.
This position represents approximately 7.4% of the outstanding common shares. Pathfinder reported sole voting power and sole dispositive power over all 399,775 shares, with no shared voting or dispositive power.
Modular Medical, Inc. is registering 193,027 shares of common stock for resale by existing holders. This includes up to 108,372 shares issuable upon exercise of inducement warrants, 32,655 shares issuable upon exercise of underwriter warrants with piggyback rights, and 52,000 shares previously issued to service providers.
The company itself is not selling shares and will not receive proceeds from these resales, but could receive up to approximately $3.2 million if all 141,077 warrants are exercised for cash, to be used for capital expenditures, working capital and general corporate purposes. As of July 31, 2026, 5,984,242 shares were outstanding, and the Nasdaq price was $2.39 per share.
Modular Medical is a medical device company focused on insulin delivery, with FDA-cleared MODD1 and Pivot patch pumps. The company has launched its tubeless Pivot insulin delivery system in the United States and begun commercial shipments and real‑world patient use.
Modular Medical, Inc. director Ellen O'Connor Vos received a grant of options to purchase 250 shares of common stock at an exercise price of $4.88 per share. The options were granted under the Outside Director Compensation Plan, were fully vested and exercisable on the grant date, and expire on June 30, 2036.
Modular Medical, Inc. director Philip Brent Sheibley received an option grant covering 250 shares of common stock. The option was granted under the company’s Outside Director Compensation Plan, is fully vested, and became exercisable on the grant date at an exercise price of $4.88 per share.
Modular Medical, Inc. director Jeff D. Goldberg received an option grant to purchase 250 shares of common stock. The option was awarded on June 30, 2026 under the company’s Outside Director Compensation Plan, with an exercise price of $4.88 per share, and was fully vested and exercisable on the grant date. The option for 250 underlying common shares expires on June 30, 2036, and represents his reported beneficial ownership of this class of derivative security following the transaction.